CNS Pharmaceuticals Files 8-K on Officer Changes and Financials
Ticker: CNSP · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1729427
| Field | Detail |
|---|---|
| Company | Cns Pharmaceuticals, Inc. (CNSP) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $580,000, $319,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financial-reporting
TL;DR
CNS Pharma 8-K: Leadership shakeup and financial updates filed Dec 16.
AI Summary
On December 16, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also includes information on compensatory arrangements for certain officers and financial statements. The company is incorporated in Nevada and its principal executive offices are located in Houston, Texas.
Why It Matters
This filing provides crucial updates on the company's leadership and financial health, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in executive officers and board composition can indicate internal shifts that may impact future performance.
Key Numbers
- 20251216 — Report Date (Earliest event reported)
- 20251217 — Filing Date (Date of submission)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What specific changes were made to the board of directors or executive officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify the names or exact roles affected in the provided text.
What type of compensatory arrangements are detailed in the filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not provided in the excerpt.
Are the financial statements included in this 8-K filing?
Yes, the filing lists 'Financial Statements and Exhibits' as an item of information.
What is the primary business of CNS Pharmaceuticals, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?
The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
Filing Stats: 1,131 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2025-12-17 08:43:58
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
- $580,000 — es for an initial annual base salary of $580,000, eligibility for an annual bonus with a
- $319,000 — 2025 cash bonus in the total amount of $319,000, paid in twelve equal monthly installme
Filing Documents
- cns_8k.htm (8-K) — 32KB
- cns_ex1001.htm (EX-10.1) — 60KB
- cns_ex1002.htm (EX-10.2) — 53KB
- 0001683168-25-009208.txt ( ) — 342KB
- cnsp-20251216.xsd (EX-101.SCH) — 3KB
- cnsp-20251216_lab.xml (EX-101.LAB) — 34KB
- cnsp-20251216_pre.xml (EX-101.PRE) — 22KB
- cns_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits No. Description 10.1 Employment Agreement between Rami Levin and CNS Pharmaceuticals, Inc. dated December 16, 2025 10.2 Separation and Severance Agreement between John Climaco and CNS Pharmaceuticals, Inc. dated December 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: December 17, 2025 3